Document is current
Any future updates will be listed below
-
Authors
Alpaugh, Melanie https://orcid.org/0000-0002-2782-5454
Lantero-Rodriguez, Juan
Benedet, Andrea L.
Manseau, Uriel
Boutin, Martine
Maiuri, Massimo
Denis, Helena L.
Masnata, Maria
Fazal, Shaline V.
Chouinard, Sylvain
Rosa-Neto, Pedro
Barker, Roger A.
Blennow, Kaj
Zetterberg, Henrik
Labib, Richard
Cicchetti, Francesca
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Huntington's Disease Society of America
Wellcome Trust
Medical Research Council
NIHR Cambridge Biomedical Research Centre
Vetenskapsrådet (2017-00915, 2022-00732, ALFGBG-715986, ALFGBG-965240, 2023-00356, 2022-01018, 2019-02397, ALFGBG-71320)
Alzheimerfonden (AF-930351, AF-939721, AF-968270)
Hjärnfonden (FO2017-0243, ALZ2022-0006, FO2022-0270)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236, JPND2021-00694)
Alzheimer's Association (ZEN-21-848495, SG-23-1038904 QC, ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C, ADSF-24-1284328-C)
European Union’s Horizon Europe research and innovation programme (101053962)
Alzheimer's Drug Discovery Foundation (201809-2016862)
European Partnership on Metrology (#22HLT07)
HORIZON EUROPE Marie Sklodowska-Curie Actions (860197)
UK Dementia Research Institute (UKDRI-1003)
- License Information
-
More Information
Article History
Received: 23 December 2024
Revised: 4 February 2025
Accepted: 7 February 2025
First Online: 6 March 2025
Declarations
:
: KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare that they have no conflict of interest. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). FC is a co-founder of Synucure Therapeutics and a consultant for Axoltis and HD immune Vienna. RAB is on the editorial board of the Journal of Neurology.
